Hims & Hers shares tumble

Stock of the Day: Hims & Hers plunges 27% after saying it will stop selling its Ozempic competitor
With Hims & Her's main source of growth set to be extinguished, Citi analysts said its full-year guidance appears "aspirational."
Hims & Hers tumbles 27% as investors fear uncertainty without compounded weight-loss drugs
Hims & Hers stock tumbled after the company confirmed it would stop selling some compounded weight-loss drugs.
Hims & Hers shares tumble after company misses on margin, says may stop selling some weight loss drugs
Hims & Hers Health reported fourth-quarter results on Monday that beat analysts’ expectations, but the stock sank in extended trading.
Hims & Hers will stop selling some weight loss drugs — and the stock plummets 27%
Hims & Hers (HIMS) stock took a steep dive, dropping more than 27%Tuesday morning — even after the millennial-focused telehealth company reported soaring sales for 2024 just the night before.
Hims is officially phasing out its copycat weight-loss drugs, and the company's stock tumbled — again
After the FDA removed semaglutide injection products from a shortage list, compounders like Hims have 60-90 days to stop making copies.
Novo Nordisk Stock Rallies on Weight-Loss Retreat by Hims & Hers
Investors are scrambling to adjust, after the telehealth specialist Hims & Hers said it would stop selling an alternative to Novo Nordisk's Wegovy and Ozempic weight-loss drugs. Hims stock stood about 17% lower at under $42.
Hims & Hers warns it may stop selling compounded weight-loss drugs
Hims & Hers said on Monday that it may no longer be able to sell compounded versions of the weight-loss drug made by Novo Nordisk because its pathway to do so closed when the U.S. FDA declared Friday that the drug's shortage was over.
Hims & Hers Shares Plunge as Costs Tied to Weight-Loss Drugs Squeeze Margins
Shares of Hims & Hers Health (HIMS) shares plunged in late trading Monday after the company reported falling margins as costs rose, overshadowing better-than-expected sales. The online healthcare provider’s fourth-quarter revenue nearly doubled year-over-year to $481.
Novo Nordisk’s stock is rallying as Hims & Hers’ stock falters. An Ozempic alternative won’t be available for long.
Novo Nordisk shares rallied on Tuesday as a maker of a weight-loss drug alternative confirmed it won’t be selling it for much ...
HIMS Earnings Preview: Will The Stock Rebound After 25% Drop?
Hims & Hers Health (NYSE:HIMS) is set to report its earnings on Monday, Feb 24 after market close. HIMS stock plunged over 25 ...
HIMS Stock Declines Following Q4 Earnings Miss, Gross Margin Contracts
Hims & Hers' revenue channels witness strong growth on the back of solid product demand in the fourth quarter.
Hims & Hers offers upbeat forecast, but stock slides after hours
Telehealth and wellness platform Hims & Hers on Monday offered a revenue outlook for the year ahead that topped Wall Street’s ...
Hims & Hers: Capitalizing On The GLP-1 Rush Before The Window Closes (Rating Upgrade)
Hims & Hers projects $725M in GLP-1 weight loss revenue for 2025, a 3.2x increase from 2024. Read why I upgrade HIMS stock ...
Why Hims & Hers Stock Dropped Today
Raising its price target on the shares to $21, reports The Fly, BofA nonetheless reiterated an "underperform" ( i.e., sell) ...
These Stocks Are Moving the Most Today: Super Micro, Nvidia, Home Depot, Palantir, Hims & Hers, Eli Lilly, MicroStrategy, and More
Super Micro has until Tuesday to file delayed financial accounts or risk being delisted by the Nasdaq stock exchange, Home ...
Hims & Hers posts Q4 beat, issues bullish outlook: why is the stock crashing?
Hims & Hers Health (HIMS) stock crashes even as the company reported better than expected Q4 2024 results and issued a bullish outlook. Read more here.